Pfizer Inc. (NYSE:PFE) Shares Bought by Lazari Capital Management Inc.

Lazari Capital Management Inc. grew its stake in Pfizer Inc. (NYSE:PFE) by 93.6% during the 1st quarter, Holdings Channel reports. The firm owned 62,380 shares of the biopharmaceutical company’s stock after purchasing an additional 30,151 shares during the quarter. Lazari Capital Management Inc.’s holdings in Pfizer were worth $1,581,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Norges Bank purchased a new stake in Pfizer during the 4th quarter worth approximately $2,328,986,000. Charles Schwab Investment Management Inc. lifted its position in shares of Pfizer by 19.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock valued at $4,124,330,000 after acquiring an additional 25,315,159 shares in the last quarter. Starboard Value LP acquired a new stake in shares of Pfizer in the fourth quarter worth approximately $407,730,000. Raymond James Financial Inc. purchased a new stake in shares of Pfizer during the fourth quarter worth approximately $274,694,000. Finally, Assenagon Asset Management S.A. raised its stake in Pfizer by 307.5% in the 1st quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company’s stock valued at $254,574,000 after purchasing an additional 7,581,030 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Cantor Fitzgerald began coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price target for the company. Finally, Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $29.17.

Pfizer Trading Up 0.3%

PFE opened at $24.04 on Tuesday. The stock has a market capitalization of $136.68 billion, a PE ratio of 17.42, a P/E/G ratio of 0.87 and a beta of 0.57. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The business’s 50 day moving average price is $23.30 and its 200 day moving average price is $24.88.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company’s quarterly revenue was down 7.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.82 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, June 13th. Shareholders of record on Friday, May 9th were paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.15%. The ex-dividend date of this dividend was Friday, May 9th. Pfizer’s dividend payout ratio (DPR) is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.